质子放疗用于局部晚期乳腺癌:演变与技术
本文综述质子放疗在局部晚期乳腺癌中的历史发展、技术演变与临床应用,重点讨论当需要 comprehensive nodal irradiation 尤其是内乳链照射时降低心肺剂量的需求。RADCOMP 是首个比较质子与光子区域淋巴结照射的大型前瞻性随机试验,2024 年完成入组(n = 1239),2025 年健康相关生活质量分析显示两组患者报告结局同样优异,但局部区域控制与主要心脏事件的主要终点仍待公布。
要点
- 质子放疗用于局部晚期乳腺癌的主要驱动是 comprehensive nodal irradiation 时降低心肺剂量。
- 技术从被动散射和均匀扫描演进为笔形束扫描和调强质子治疗。
- RADCOMP 试验 2024 年完成入组(n = 1239),主要终点局部区域控制和主要心脏事件仍待公布。
核心结论
- 质子放疗已成为局部晚期乳腺癌的重要技术,尤其适用于 comprehensive nodal irradiation 且需照射内乳链时降低心肺剂量。
- RADCOMP 试验 2025 年健康相关生活质量分析显示质子与光子两组患者报告结局同样优异,但主要终点局部区域控制和主要心脏事件仍待公布。
研究设计与样本
- 本文为 critical review,回顾质子放疗用于局部晚期乳腺癌的历史发展、技术演变和临床应用。
- RADCOMP 是首个比较质子与光子区域淋巴结照射的大型前瞻性随机试验,2024 年完成入组(n = 1239)。
主要发现
- 自 2010 年首批局部晚期乳腺癌且心脏解剖不利患者的临床质子经验以来,质子放疗技术显著演变。
- 质子计划对轮廓准确性、摆位和射程不确定性比光子计划更敏感,且质子入射剂量行为与光子皮肤保护效应根本不同。
关键数值与推荐
- RADCOMP 2025 年健康相关生活质量分析显示质子与光子两组患者报告结局同样优异。
- RADCOMP 主要终点局部区域控制和主要心脏事件仍待公布。
临床怎么用
- 靶区勾画和计划稳健性评估需要针对疾病特异性的审慎决策。
- 本文为放射肿瘤科医生、物理师和剂量师提供实用指导,尤其是质子乳腺经验早期阶段的中心。
局限性
- 除 RADCOMP 外,多数已发表经验仍为单中心且技术异质性大。
- RADCOMP 主要终点局部区域控制和主要心脏事件仍待公布,长期结果尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proton therapy has emerged as an important technique for locally advanced breast cancer (LABC), driven primarily by the need to reduce cardiopulmonary dose during comprehensive nodal irradiation, particularly when the internal mammary chain is targeted. Since the first clinical proton experience in patients with LABC and unfavorable cardiac anatomy in 2010, proton radiation therapy for LABC has evolved considerably: delivery technique has progressed from passive scattering and uniform scanning to pencil beam scanning and intensity modulated proton therapy, whereas breast radiation oncology overall has shifted from field-based to volumetric, contour-driven planning. RADCOMP, the first large prospective randomized trial comparing proton and photon regional nodal irradiation, completed accrual in 2024 (n = 1239); its 2025 health-related quality-of-life analysis showed similarly excellent patient-reported outcomes in both arms, whereas the trial's primary endpoints of locoregional control and major cardiac events remain pending. Beyond RADCOMP, most published experience remains single-institutional and technically heterogeneous. This critical review examines the historical development, technical evolution, and clinical application of proton therapy for LABC, with attention to contouring philosophy, robustness evaluation, and optimization of normal tissue-related side effects. Because proton plans are more sensitive to contour accuracy, setup, and range uncertainty than photon plans, and because proton entrance-dose behavior differs fundamentally from the photon skin-sparing effect, target delineation and plan robustness assessment require deliberate, disease-specific decision-making. We provide practical guidance for radiation oncologists, physicists, and dosimetrists, particularly those at centers early in their proton breast experience, and outline priorities for standardized reporting as long-term RADCOMP outcomes mature.
引用
- MacDonald SM, Kirova Y, Campbell L, et al. Proton Radiation for Locally Advanced Breast Cancer: Evolution and Techniques. Int J Radiat Oncol Biol Phys. 2026. PMID: 42617887. doi:10.1016/j.ijrobp.2026.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。